SEC Form 4 · accession 0001562180-19-000855
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Briggs Morrison
Officer — Chief Executive Officer · Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001395937
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.38 | Feb 6, 2019 | A | 354,000 | A | — | Feb 6, 2029 | Common Stock | 354,000 | 354,000 | D |
Explanation of responses
- F1The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 177,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 177,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones.